Glenmark Pharma Launches India S First Triple Drug Combo For Type 2 Diabetes

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Glenmark Pharma launches India's first Triple-Drug Combo for type 2 Diabetes

ri-calendar-2-lineOct 18, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Glenmark Pharmaceuticals Ltd saw a rise in its shares during morning trading on October 18, following the announcement of its launch of a triple-drug fixed-dose combination (FDC) comprising Teneligliptin, Dapagliflozin, and Metformin. This combination targets type 2 diabetes in adults with comorbidities, making Glenmark the first company in India to introduce this treatment. Taken once daily under prescription, the drug enhances glycemic control in type 2 diabetes patients.

 

Priced at Rs 14 per tablet, this product is expected to reduce daily therapy costs by 30%. Marketed under the name Zita DM, it contains DPP4 inhibitor Teneligliptin (20mg), SGLT2 inhibitor Dapagliflozin (10mg), and Metformin SR (500mg/1000mg) in a fixed dose.

 

Alok Malik, President and Business Head – India Formulations at Glenmark Pharma, expressed pride in the introduction of Zita DM. He emphasized that it offers an effective and economical solution for adult patients dealing with high HbA1c levels and other comorbidities, while also reducing significant renal and cardiac adverse events.

 

Glenmark reported that its Zita line of medicines annually supports approximately 1.75 million type 2 diabetic patients in India. According to IQVIA sales data from the 12 months ending August 2023, the market for oral anti-diabetic drugs in the country is estimated at Rs 12,522 crore, reflecting a 6.5% yearly growth.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartCommodities

Why Gold Remains a Safe Haven Amid Global Economic Shifts in 2025

0 people read

4 mins read . Sep 5, 2025

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions